Inhibitors of serine proteases, particularly HCV NS3-NS4A...

Details Inhibitors of serine proteases, particularly HCV NS3-NS4A... Inhibitors of serine proteases, particularly HCV NS3-NS4A...

2007-04-24

2007-04-24

Kumar, Shailendra (Department: 1621)

Organic compounds -- part of the class 532-570 series

Organic compounds

Nitrogen attached directly or indirectly to the purine ring...

C544S405000, C548S523000, C514S255010, C514S422000

Reexamination Certificate

active

10964214

ABSTRACT:
The present invention relates to compounds of formula I:or a pharmaceutically acceptable salt or mixtures thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3–NS4A protease. As such, they act by interfering with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The invention further relates to compositions comprising these compounds either for ex vivo use or for administration to a patient suffering from HCV infection and to processes for preparing the compounds. The invention also relates to methods of treating an HCV infection in a patient by administering a composition comprising a compound of this invention. The invention further relates to processes for preparing these compounds.

REFERENCES:
patent: 5484801 (1996-01-01), Al-Razzak et al.
patent: 5807876 (1998-09-01), Armistead et al.
patent: 5948436 (1999-09-01), Al-Razzak et al.
patent: 6037157 (2000-03-01), Norbeck et al.
patent: 6054472 (2000-04-01), Armistead et al.
patent: 6344465 (2002-02-01), Armistead et al.
patent: 6498178 (2002-12-01), Stamos et al.
patent: 6541496 (2003-04-01), Armistead et al.
patent: 7109172 (2006-09-01), Britt et al.
patent: 0 675 112 (1995-10-01), None
patent: WO 94/14436 (1994-07-01), None
patent: WO 95/07696 (1995-03-01), None
patent: WO 95/09614 (1995-04-01), None
patent: WO 97/40028 (1997-10-01), None
patent: WO 98/17679 (1998-04-01), None
patent: WO 98/40381 (1998-09-01), None
patent: WO 00/56331 (2000-09-01), None
patent: WO 02/08244 (2002-01-01), None
patent: WO 02/18369 (2002-03-01), None
patent: WO 03/006490 (2003-01-01), None
patent: WO 03/035060 (2003-05-01), None
patent: WO 03/087092 (2003-10-01), None
patent: WO 2004/092161 (2004-10-01), None
patent: WO 2004/092612 (2004-10-01), None
Alberti, A. et al., “Natural History of Hepatitis C,”J. Hepatology, 31., (Suppl. 1), pp. 17-24 (1999).
Alter, M. J. “Hepatitis C Virus Infection in the United States,”J. Hepatology, 31., (Suppl. 1), pp. 88-91 (1999).
Alter, M.J. et al., The Epidemiology of Viral Hepatitis in the United States,Gastroenterol. Clin. North Am., 23, pp. 437-455 (1994).
Bartenschlager, R.et. al., “Nonstructural Protein 3 of the Hepatitis C Virus Encodes a Serine-Type Proteinase Required for Cleavage at the NS3/4 and NS4/5 Junctions,”J. Virol., 67, pp. 3835-3844 (1993).
Chambers, T.J. et. al., “Evidence that the N-terminal Domain of Nonstructural Protein NS3 From Yellow Fever Virus is a Serine Protease Responsible for Site-Specific Cleavages in the Viral Polyprotein”,Proc. Natl. acad. Sci. USA, 87, pp. 8898-8902 (1990).
Choo, Q.L. et. al., “Genetic Organization and Diversity of the Hepatitis C Virus.”Proc. Natl. Acad. Sci. USA, 88, pp. 2451-2455 (1991).
Clayette, P. et al., “IFN-tau, A New Interferon Type I with Antiretroviral activity”Pathol. Biol. (Paris) 47, pp. 553-559 (1999).
Davis et al. “Future Options for the Management of Hepatitis C.”Seminars in Liver Disease19, pp. 103-112 (1999).
Field, L. et al., “Organic disulfides and Related Substances. 42. Synthesis and Properties of Some Tertiary Disulfides, Especially Involving Penicillamine,”J. Org. Chem., pp. 2624-2629 (1979).
Grakoui, A. et. al., “Charactérization of the Hepatitis C Virus-Encoded Serine Proteinase: Determination of Proteinase-Dependent Poolyprotein Cleavage Sites,”J. Virol., 67, pp. 2832-2843 (1993).
Grakoui, A. et. al., “Expression and Identification of Hepatitis C Virus Polyprotein Cleavage Products,”J. Virol., 67, pp. 1385-1395 (1993).
Holladay, M.W. et al., “Dual Antagonists of Platelet Activiating Factor and Histamine. Identification of Structural Requirements for Dual Activity of N-Acyl-4-(5,6-dihydro-11 H-benzo[5,6]cyclohepta-[1,2-b]pyridin-11-ylidene)piperidines,”J. Med. Chem., 34, pp. 457-461 (1991).
Iwarson, S. “The Natural Course of Chronic Hepatitis C,”FEMS Microbiology Reviews, 14, pp. 201-204 (1994).
Janssen, H. L. A. et al. “Suicide Associated with Alfa-Interferon Therapy for Chronic Viral Hepatitis,”J. Hepatol., 21, pp. 241-243 (1994).
Johansson, Anja et al., “Acyl sulfonamides as potent protease inhibitors of the hepatitis C virus full-length NS3 (protease-helicase/NTPase): A comparative study of different c-terminals,”Bioorganic&Medicinal Chemistry, Elsevier Science Ltd, GB, vol. 11, pp. 2551-2568 (2003).
Kanamasa, S. et al., “Highly Diastereoselective Michael Addition of Lithiated Camphor Imines of GLycine Esters to α,β-Unsaturated Esters. Synthesis of Optically Pure 5-Oxo-2,4-pyrrolidinedicarboxylates of Unnatural Stereochemistry,”J. Org. Chem, 56, pp. 2875-2883 (1991).
Kao, J.H., et al., “Efficacy of Consensus Interferon in the Treatment of Chronic Hepatitis C”J. Gastroenterol. Hepatol. 15, pp. 1418-1423 (2000).
Kato, N. et al., “Molecular Cloning of the Human Hepatitis C Virus Genome From Japanese Patients with Non-A, Non-B hepatitis,”Proc. Natl. Acad. Sci. USA, 87, pp. 9524-9528 (1990).
Kempf, D.J. et al., “Symmetry-Based Inhibitors of HIV Protease. Structure-Activity studirs of Acylated 2,4-Diamino-1,5-diphenyl-3-hydroxypentane and 2,5-Diamino-1,6-diphenylhexane-3,4-diol,”J. Med. Chem., pp. 320-330 (1993).
Kew, M.C. “Hepatitis C and Hepatocellular Carcinoma”,FEMS Microbiology Reviews, 14, pp. 211-220 (1994).
Lavanchy, D. “Global Surveillance and Control of Hepatitis C,”J. Viral Hepatitis, 6, pp. 35-47 (1999).
Lin, C. et al., “Hepatitis C Virus NS3 Serine Proteinase:Trans-Cleavage Requirements and Processing Kinetics”,J. Virol., 68, pp. 8147-8157 (1994).
Markland, W. et al., “Board-Spectrum Antiviral Activity of the IMP Dehydrogenase Inhibitor VX-497: a Comparison with Ribavirin and Demonstration of Antiviral Additivity with Alpha Interferon,”Antimicrobial&Antiviral Chemotherapy, 44, p. 859 (2000).
Moradpour, D. et al., “Current and Evolving Therapies for Hepatitis C,”Eur. J. Gastroenterol. Hepatol., 11, pp. 1199-1202 (1999).
Perni, Robert B. et al., “Inhibitors of hepatitis C virus NS3.4A protease. Part 3: P2 Proline Variants,”Bioorganic&Medicinal Chemistry Letters, Oxfrod GB, vol. 14, pp. 1939-1942 (2004).
Perni, Robert B. et al., “Inhibitors of hepatitis C virus NS3.4A protease 2. Warhad SAR and optimization,”Bioorganic&Medicinal Chemistry Letters, vol. 14, pp. 1441-1446 (2004).
Perni, Robert B. et al., “Inhibitors of hepatitis C virus NS3cntdot4A protease 1. Non-charged tetrapeptide variants,”Bioorganic&Medicinal Chemistry Letters, vol. 13, pp. 4059-4063 (2003).
Poliakov, A. et al., “Structure-activity relationship for the selectivity of hepatitis C virus NS3 protease inhibitors”BBA—General Subject, Elsevier Science Publishers, NL, vol. 1672, 51-59 (2004).
Reddy, K.R. et al. Efficacy and Safety of Pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C (Hepatology, pp. 433-438 (2001).
Renault, P.F. et al., “Side Effects of Alpha Interferon,”Seminars in Liver Disease, 9, pp. 273-277, (1989).
Saito, I. et al., “Hepatitis C Virus Infection is Associated with the Development of Hepatocellular Carcinoma,”Proc. Natl. Acad. Sci. USA, 87, pp. 6547-6549 (1990).
Sauder, D.N. “Immunomodulatory and Pharmacologic Properties of Imiquimod”J. am. Acad. Dermatol., 43 pp. S6-11 (2000).
Takamizawa, A. et. al., “Structure and Organization of the Hepatitis C Virus Genome Isolated From Human Carriers,”J. Virol., 65, pp. 1105-1113 (1991).
Tazulakhova, E.B. et al., “Russian Experience in Screening, analysis, and Clinical Application of Novel Interferon Inducers”J. Interferon Cytokine Res., 21 pp.65-73, 2001.
Tomei, L. et al., “NS3 is a serine protease required for processing of hepatitis C virus polyprotei

Affiliated with

Also associated with

Rating

Inhibitors of serine proteases, particularly HCV NS3-NS4A... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Inhibitors of serine proteases, particularly HCV NS3-NS4A..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of serine proteases, particularly HCV NS3-NS4A... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3754460